Through quantitative structure-activity relationship (QSAR) models, predictions can be made for a drug substance itself, intermediates, prioritizing experimental inquiries into the potential effects of newly identified drugs of abuse, and more. FDA’s Division of Applied Regulatory Science’s (DARS) computational toxicology and pharmacology research has been focused on the development of highly curated data sets and QSAR models for endpoints of regulatory interest.